Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650704 | 0.80 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3CBCDK2EIF4A3 | |
| SCHEMBL25200670 | 0.70 | AXL (0.44) | PIK3CAPIK3CDPIK3CBCDK2 | |
| SCHEMBL22650905 | 0.67 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL24147819 | 0.67 | PIK3CA (0.43) | KDRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL24147766 | 0.67 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3079081 | 0.67 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL24149172 | 0.66 | PIK3CA (0.44) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL15951734 | 0.66 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL3074661 | 0.65 | PIK3CA (0.39) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL20400308 | 0.65 | KDR (0.41) | KDRPSMB5CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | KDR 2081/4885PSMB5 2342/4885PIK3CA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.